A panelist discusses how hypertension, often called the “silent killer,” remains a widespread yet underdiagnosed and undertreated condition globally, contributing significantly to cardiovascular and kidney-related morbidity despite being largely preventable and manageable.
Explore the complexities of resistant hypertension, its causes, and effective treatment strategies to achieve better blood pressure control.
Dr Rader begins his contribution to a discussion surrounding resistant hypertension, defining common parameters for diagnosis.
Explore effective strategies for managing resistant hypertension, including lifestyle changes, medication adjustments, and advanced treatment options.
A panelist discusses how resistant hypertension is defined as blood pressure exceeding 130/80 despite treatment with three properly dosed medications or controlled pressure requiring four or more medications, affecting one in five or six hypertension patients, and emphasizes the importance of differentiating true resistance from pseudo-resistance through proper measurement techniques and systematic evaluation for secondary causes.
Dr Rader outlines the critical impact of resistant hypertension, and emphasizes the criticality of early identification of risk factors.
Managing hypertension in complex patients involves navigating comorbidities, treatment inertia, and care fragmentation for optimal outcomes.
A panelist discusses how comorbidities like chronic kidney disease, obesity, and diabetes complicate resistant hypertension treatment by limiting therapeutic options and affecting medication adherence, while emphasizing that treatment should begin with lifestyle modifications and rationalizing the foundational three-drug regimen before intensifying therapy.
A panelist discusses how successful treatment requires selecting the right three to five medications with minimal side effects, using once-daily combination pills to maximize adherence, and engaging patients as active participants through structured home blood pressure monitoring protocols.
A panelist discusses how patient compliance remains the primary obstacle to blood pressure control despite effective medications being available, while clinical inertia among healthcare providers and medication side effects affecting electrolytes and kidney function add additional complexity to resistant hypertension management.
Discover how Aroittenan effectively manages hypertension in patients with chronic kidney disease, offering a reliable alternative for those intolerant to standard treatments.
A panelist discusses how spironolactone is typically the first fourth medication added for resistant hypertension but has limitations in patients with kidney disease or electrolyte issues, necessitating alternative strategies like renal denervation and highlighting the need for multiple treatment approaches to avoid polypharmacy-related adherence problems.
A panelist discusses how resistant hypertension is defined as persistently high blood pressure (>135/85 mm Hg) despite patients being on multiple antihypertensive medications and occurs in approximately 1 in 5 compliant patients.
Discover innovative strategies and tools for effective hypertension management, enhancing patient care and treatment outcomes in today's healthcare landscape.
A panelist discusses how aprocitentan represents the first new class of antihypertensive drugs in decades as a dual endothelin antagonist that effectively reduces blood pressure in resistant hypertension patients, particularly those with chronic kidney disease, though it requires monitoring for leg swelling and avoiding use in pregnancy.
A panelist discusses how the underlying causes of resistant hypertension remain largely mysterious, though physicians must screen for secondary causes like cortisol-producing tumors or coarctation of the aorta while recognizing that some patients simply don’t respond to normally effective medications.
A panelist discusses how patient compliance remains the primary obstacle to blood pressure control despite effective medications being available, while clinical inertia among healthcare providers and medication side effects affecting electrolytes and kidney function add additional complexity to resistant hypertension management.
A panelist discusses how the epidemic of uncontrolled hypertension affects over 50% of patients and emphasizes that with emerging new drugs, devices, and technologies, healthcare providers will soon need to move beyond simply prescribing three medications and instead systematically utilize all available treatment options to achieve blood pressure control.
A panelist discusses how comorbidities like obesity, diabetes, and kidney disease significantly contribute to resistant hypertension through mechanisms including dietary sodium excess, arterial stiffening, and hormonal disruption from the renin-aldosterone system
A panelist discusses how aprocitentan is most beneficial for patients who have tried multiple antihypertensive medications without success, particularly those with chronic kidney disease, abnormal kidney function, or hyperkalemia who cannot tolerate other medication classes that affect electrolyte levels.
A panelist discusses how treatment strategies progress from standard 3-drug regimens (thiazide diuretics, calcium channel blockers, and ACE inhibitors/ARBs) to fourth-line options like endothelin antagonists or aldosterone antagonists, while addressing information overload and the need for weight management drugs.
A panelist discusses how future improvements in resistant hypertension management will focus on overcoming medication noncompliance through long-acting injectable treatments and device-based options like renal denervation, while emphasizing best practices including accurate out-of-office blood pressure measurements and systematic treatment protocols targeting 130/80 mmHg.
A panelist discusses how healthcare providers must become lifestyle coaches who understand patients' daily routines and circumstances to develop realistic medication schedules that address practical barriers to adherence in complex polypharmacy regimens.
A panelist discusses how aprocitentan, a dual endothelin receptor antagonist, represents a breakthrough treatment that blocks both A and B receptors to achieve clinically meaningful blood pressure reductions in resistant hypertension patients.
A panelist discusses real-world clinical experience with aprocitentan showing remarkable blood pressure improvements in heavily pretreated patients, with manageable side effects like mild fluid retention that can be addressed through diuretic adjustments.
A panelist discusses the importance of comprehensive patient reassessment before advancing to dual endothelin receptor antagonists or aldosterone antagonists, emphasizing that successful resistant hypertension management requires integration of advanced pharmacological therapies with lifestyle interventions and ongoing patient support.
